证券代码：688181 证券简称：八亿时空 公告编号：2025-045 北京八亿时空液晶科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 13 日 1、议案名称：《关于取消监事会、修订<公司章程>并办理工商变更登记的议案》 审议结果：通过 表决情况： （二） 股东大会召开的地点：北京市房山区燕山东流水 20 号北京八亿时空液晶 科技股份有限公司 316 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 76 | | --- | --- | | 普通股股东人数 | 76 | | 2、出席会议的股东所持有的表决权数量 | 34,112,341 | | 普通股股东所持有表决权数量 | 34,112,341 | | 3、出席会议的股东所持有表决权数量占公司表决权数 ...

Core Viewpoint - The company, 8 Billion Space (688181.SH), announced the resignation of non-independent director Liu Jun due to the optimization of the corporate governance structure, while he will continue to serve as the deputy general manager and director of the comprehensive operation center [1] Group 1 - Liu Jun submitted a written resignation report to the board of directors [1] - The resignation is part of the company's efforts to optimize its governance structure [1] - Liu Jun will retain his positions as deputy general manager and director of the comprehensive operation center after resigning from the board [1]

Group 1 - The core viewpoint of the news is that Ba Yi Shi Kong's stock has shown fluctuations in price and trading volume, with a current market capitalization of 4.578 billion yuan and a recent increase of 2.13% in stock price [1] - As of September 30, 2025, Ba Yi Shi Kong reported a revenue of 645 million yuan, representing a year-on-year growth of 17.60%, while the net profit attributable to shareholders decreased by 26.06% to 45.5688 million yuan [2] - The company has distributed a total of 128 million yuan in dividends since its A-share listing, with 41.2998 million yuan distributed over the past three years [3] Group 2 - The company is primarily engaged in the research, development, production, and sales of display liquid crystal materials, with its main business revenue composition being 90.87% from mixed liquid crystals [1] - As of September 30, 2025, the number of shareholders increased by 27.07% to 12,200, while the average circulating shares per person decreased by 21.30% to 11,027 shares [2] - The company is categorized under the electronic industry, specifically in optical optoelectronics and panels, and is associated with concepts such as photoresists, innovative drugs, LEDs, advanced packaging, and specialized new [1]

Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 31.427 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 5.743 billion yuan [1] - A total of 248 stocks saw net inflows, while 343 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 332 stocks rose, with four stocks hitting the daily limit up, including Fangyuan Co. and Jindike [1] - The top three stocks with the highest net inflows were: - Purun Co. with a net inflow of 214 million yuan - Shengkong Co. with 171 million yuan - Trina Solar with 150 million yuan [1] Continuous Fund Flow Analysis - There are 60 stocks that have seen continuous net inflows for more than three trading days, with Zhonggang Luoni leading at 13 consecutive days of inflow [2] - Conversely, 125 stocks have experienced continuous net outflows, with Bayi Space leading at 14 consecutive days of outflow [2] Top Net Inflow Stocks - The top stocks by net inflow include: - Purun Co. with 21.363 million yuan and a 13.47% increase - Shengkong Co. with 17.116 million yuan and a 20% increase - Trina Solar with 15.042 million yuan and a 0.09% increase [2][3] Top Net Outflow Stocks - The stocks with the highest net outflows include: - SMIC with a net outflow of 699 million yuan and a 1.72% decrease - Guodun Quantum with 543 million yuan outflow - Lanqi Technology with 499 million yuan outflow [1]

北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688181 证券简称：八亿时空 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 11 月 1 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议资料 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议资料目录 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议须知......3 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议议程......5 议案一：《关于取消监事会、修订<公司章程>并办理工商变更登记的议案》... 7 议案二：《关于修订、废止及制定公司部分治理制度的议案》............................8 北京八亿时空液晶科技股份有限公司 2025 年第二次临时股东大会会议须知 各位股东及股东代表： 为维护股东的合法权益，确保股东及股东代表在北京八亿时空液晶科技股份 有限公司（以下简称"公司"）2025 年第二次临时股东大会期间依法行使权利， 保证股东大会的正常秩序和议事效率，依据 ...

Core Viewpoint - The company, Beijing Eight Billion Space Liquid Crystal Technology Co., Ltd., has initiated a share repurchase program to enhance shareholder value and potentially support employee stock ownership plans [1][2]. Summary by Sections 1. Basic Information on Share Repurchase - On May 16, 2025, the company’s board approved a share repurchase plan using its own funds and a special loan of up to 70 million RMB from Shanghai Pudong Development Bank [1] - The repurchase will target a maximum price of 40 RMB per share, with a total repurchase amount between 50 million RMB and 100 million RMB [1] - The repurchase period is set for 12 months from the board's approval date [1] 2. Progress of Share Repurchase - As of October 31, 2025, the company has repurchased a total of 477,000 shares, representing 0.35% of its total share capital of 134,481,546 shares [2] - The highest price paid for the repurchased shares was 28.20 RMB, while the lowest was 27.69 RMB, with a total expenditure of approximately 13.37 million RMB (excluding transaction fees) [2] - The repurchase activities are in compliance with relevant laws and the company's repurchase plan [2] 3. Other Matters - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [3]

Core Viewpoint - On November 3, the company announced that it did not conduct any share buybacks in October 2025 [2] Company Summary - The company, 八亿时空, released an announcement regarding its share buyback activities [2]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The investment logic in the pharmaceutical sector is shifting from policy pressure to innovation-driven growth, with the "14th Five-Year Plan" directly supporting the development of innovative drugs and medical devices [8][26] - The industry is witnessing a transition from rapid following to original innovation, as demonstrated by Chinese companies showcasing their global competitiveness and pipeline value at the 2025 ESMO conference [8][26] - The recent approval of innovative drugs and the successful listing of companies on the STAR Market indicate a supportive capital market for innovative pharmaceutical enterprises [8][26] Industry Review - The pharmaceutical and biotechnology industry index increased by 1.89%, ranking 20th among 31 primary industries, underperforming the CSI 300 index which rose by 2.80% [5][16] - The sub-industries of medical research outsourcing and vaccines showed the highest gains, with increases of 5.26% and 4.19% respectively, while medical devices and traditional Chinese medicine experienced declines of 1.21% and 0.56% [5][16] - As of October 31, 2025, the industry’s PE (TTM, excluding negative values) was 30.67x, up from 30.08x in the previous period, indicating an upward valuation trend but still below the average [21] Company Dynamics - A total of 36 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 805 million yuan, with 4 companies increasing holdings by 120 million yuan and 32 companies reducing holdings by 925 million yuan [5][6] - Among the 501 tracked companies, 499 have disclosed their performance for the first three quarters of 2025, with 53 companies reporting a net profit growth of 100% or more, and 69 companies reporting growth between 30% and 100% [6] Investment Recommendations - Focus on companies with strong positions in innovative drugs and cutting-edge technology platforms, particularly those involved in ADC, bispecific/multispecific antibodies, and cell therapy, which can provide high potential for international market expansion [8] - Pay attention to the CXO industry, which is expected to see increased demand due to the recovery of innovative drug development and commercialization, especially for leading companies with strong service capabilities in new technology areas [8]

北京八亿时空液晶科技股份有限公司 证券代码：688181 证券简称：八亿时空 公告编号：2025-044 本次回购股份符合相关法律法规及公司回购股份方案的规定。 三、其他事项 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/5/17 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 月 16 5 | 5 | 日~2026 | 年 | 月 | 15 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 477,000股 | | | | | | | 累计已回购股数占总股本比例 | 0.35% | | | | ...

Summary of Conference Call for Company and Industry Analysis Company Overview - **Company**: 八亿时空 (Eight Billion Space) - **Industry**: Semiconductor materials, LCD materials, OLED materials, pharmaceuticals, and pesticides Key Points and Arguments Production and Revenue Projections - The company has maximized production capacity and economic value at the 上虞基地 (Shangyu Base) through programmatic, standardized, and intelligent processes, achieving ton-level mass production delivery in July 2023. Expected revenue for 2025 is over 20 million yuan [2][3] - 南通占鼎材料 (Nantong Zhangding Materials) is preparing for the second phase of production at its Gansu factory, expected to start next month, adding over 100 tons of fluorinated liquid capacity monthly. Current monthly shipment from the first phase is about 10 tons [2][5] Market Demand and Clientele - The company holds orders worth approximately 500 million yuan, with significant demand for fluorinated liquids, indicating that even with the second phase's output, market demand will not be fully met [2][7] - Major clients include Samsung and Hynix, indicating strong ties with leading semiconductor manufacturers [2][5] LCD Business Insights - The LCD segment remains a stable cash flow source, although growth potential for display LCDs is limited. Non-display LCDs, such as adjustable glass for vehicles, show promising demand, potentially becoming a future growth point [2][9] - Domestic companies are rising, impacting the market share of overseas firms, thus providing opportunities for domestic market share growth [2][9] OLED Materials Strategy - The company focuses on front-end materials in the OLED sector, leveraging its advantages in monomer synthesis and production capacity at the Shangyu Base. The company is selective in order acceptance to maintain gross margins amid fierce domestic competition [2][9][11] - Despite a challenging overseas market for OLED materials, there is significant growth potential in the domestic market, with a year-on-year revenue increase of approximately 30% in Q3 [10][11] Pharmaceutical and Pesticide Segments - The pharmaceutical segment focuses on innovative and generic drug intermediates, adjusting product selection strategies due to industry adjustments and oversupply. Expected revenue for this segment is several million yuan this year, potentially exceeding 100 million yuan next year [4][13][14] - The pesticide segment benefits from green channel qualifications, contributing to revenue growth [4][13] Semiconductor Materials - In the semiconductor photoresist sector, the company is a domestic leader, collaborating with top firms to provide customized services. Plans include consolidating the domestic market before expanding internationally [4][15] Strategic Product Development - The company emphasizes strategic selection in its knife belt products, aiming to enhance competitiveness through optimized supply chains. Expected contributions from this segment could reach tens of millions in revenue [4][12] - The PSPI business faces intense competition, prompting the company to explore differentiated survival strategies, particularly in the non-fluorinated PSPI field [4][16] Supply Chain and Production Integration - The Shangyu Base will facilitate integrated production of LCD raw materials, with a focus on in-house production of certain materials to leverage proprietary technology and processes [4][17][18] Financial Reporting and Earnings - The company does not consolidate earnings from its investment in 詹宁 (Zhanning) as it is not a controlling entity, thus these projects are accounted for as investments rather than revenue [4][19] This summary encapsulates the key developments and strategic directions of 八亿时空 and its associated industries, highlighting growth opportunities, market dynamics, and production capabilities.